Clinical Trialsargenx Halts Phase 3 UNITY Study of Efgartigimod After Futility Review in S... argenx Halts Phase 3 UNITY Study of Efgartigimod After Futility Review in S... Read Post »
Drugs Safety AlertUK Revokes IXCHIQ Marketing Authorization After Benefit-Risk Review UK Revokes IXCHIQ Marketing Authorization After Benefit-Risk Review Read Post »
New Drug ApprovalFDA Approves Rhapsido as First Treatment for Symptomatic Dermographism FDA Approves Rhapsido as First Treatment for Symptomatic Dermographism Read Post »
New Drug ApprovalFDA Approves TUKYSA as First-Line Maintenance in Breast Cancer FDA Approves TUKYSA as First-Line Maintenance in Breast Cancer Read Post »
Clinical TrialsZealand’s Petrelintide Shows 9.2% Weight Loss and HbA1c Benefit in ZU... Zealand’s Petrelintide Shows 9.2% Weight Loss and HbA1c Benefit in ZU... Read Post »
Clinical TrialsRezdiffra Shows Consistent Response Across MASH Genetic Risk Groups Rezdiffra Shows Consistent Response Across MASH Genetic Risk Groups Read Post »
Clinical TrialsPulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 ... PulseSight Reports Favorable Safety and Early Efficacy Signals for PST-611 ... Read Post »
Clinical TrialsMUVON Reports Sustained Benefit at 12 Months in SUI Study MUVON Reports Sustained Benefit at 12 Months in SUI Study Read Post »
Clinical TrialsEpicrispr’s EPI-321 Shows Increased Muscle Volume and Strength at Six Mon... Epicrispr’s EPI-321 Shows Increased Muscle Volume and Strength at Six Mon... Read Post »
Clinical TrialsViiV Healthcare’s Cabenuva Shows Superior Viral Suppression in CROWN Stud... ViiV Healthcare’s Cabenuva Shows Superior Viral Suppression in CROWN Stud... Read Post »
Clinical TrialsArriVent’s Firmonertinib Fails Primary PFS Endpoint Despite Higher ORR in... ArriVent’s Firmonertinib Fails Primary PFS Endpoint Despite Higher ORR in... Read Post »
Clinical TrialsKairos Reports Significant PFS Improvement With ENV-105 in mCRPC Kairos Reports Significant PFS Improvement With ENV-105 in mCRPC Read Post »
Clinical TrialsLundbeck Reports Increased Good ON-Time and Reduced Dyskinesia in Phase Ib ... Lundbeck Reports Increased Good ON-Time and Reduced Dyskinesia in Phase Ib ... Read Post »
Clinical TrialsEpcoritamab Plus R-CHOP Cuts DLBCL Progression Risk by 51% Epcoritamab Plus R-CHOP Cuts DLBCL Progression Risk by 51% Read Post »
Clinical TrialsVaxcyte Reports Positive Phase 3 Results for 31-Valent Pneumococcal Vaccine... Vaxcyte Reports Positive Phase 3 Results for 31-Valent Pneumococcal Vaccine... Read Post »
Clinical TrialsBridgeBio’s BBP-418 Shows Cardiac Biomarker Gains in LGMD2I/R9 BridgeBio’s BBP-418 Shows Cardiac Biomarker Gains in LGMD2I/R9 Read Post »
Clinical TrialsRevolution Medicines Begins Phase 3 RASolute 309 Trial of Daraxonrasib and ... Revolution Medicines Begins Phase 3 RASolute 309 Trial of Daraxonrasib and ... Read Post »
Clinical TrialsAlterity’s ATH434 Shows 52% Slower Functional Decline in Adjusted Phase 2... Alterity’s ATH434 Shows 52% Slower Functional Decline in Adjusted Phase 2... Read Post »
Clinical TrialsLEQSELVI Shows Sustained Hair Regrowth and Consistent Safety Through Two Ye... LEQSELVI Shows Sustained Hair Regrowth and Consistent Safety Through Two Ye... Read Post »
Clinical TrialsRina-S Shows Durable Responses in Platinum-Resistant Ovarian Cancer in RAIN... Rina-S Shows Durable Responses in Platinum-Resistant Ovarian Cancer in RAIN... Read Post »
Clinical TrialsPfizer’s Ritlecitinib Improves Facial and Total-Body Repigmentation in Ph... Pfizer’s Ritlecitinib Improves Facial and Total-Body Repigmentation in Ph... Read Post »
Clinical TrialsBiogen Reports Encouraging 52-Week Results for Litifilimab in Cutaneous Lup... Biogen Reports Encouraging 52-Week Results for Litifilimab in Cutaneous Lup... Read Post »
New Drug ApprovalJaypirca FDA Approval Expands Pirtobrutinib Use in CLL/SLL Jaypirca FDA Approval Expands Pirtobrutinib Use in CLL/SLL Read Post »
Clinical TrialsFezolinetant Improves Vasomotor Symptoms and Sleep in Phase 4 OPTION-VMS St... Fezolinetant Improves Vasomotor Symptoms and Sleep in Phase 4 OPTION-VMS St... Read Post »
Clinical TrialsEcopipam Shows Tic Reduction Through 18 Months in Tourette Syndrome Ecopipam Shows Tic Reduction Through 18 Months in Tourette Syndrome Read Post »
Clinical TrialsICONIC-TOTAL Reports 2-Year ICOTYDE Data Showing Sustained Psoriasis Cleara... ICONIC-TOTAL Reports 2-Year ICOTYDE Data Showing Sustained Psoriasis Cleara... Read Post »
Clinical TrialsRINVOQ Shows Continued Repigmentation in Vitiligo Through Week 76 in Viti-U... RINVOQ Shows Continued Repigmentation in Vitiligo Through Week 76 in Viti-U... Read Post »
Clinical TrialsRegeneron’s Ubamatamab Shows Durable Responses in Advanced LGSOC Regeneron’s Ubamatamab Shows Durable Responses in Advanced LGSOC Read Post »
Clinical TrialsTrevogrumab Preserved Lean Mass During Semaglutide Weight Loss in Phase 2 C... Trevogrumab Preserved Lean Mass During Semaglutide Weight Loss in Phase 2 C... Read Post »
Clinical TrialsWegovy Reduced Liver Fat in Adults with Obesity in Exploratory STEP-UP Anal... Wegovy Reduced Liver Fat in Adults with Obesity in Exploratory STEP-UP Anal... Read Post »
Clinical TrialsKailera Reports Flexible Ribupatide Injection Sites and Early Weight-Loss S... Kailera Reports Flexible Ribupatide Injection Sites and Early Weight-Loss S... Read Post »
Clinical TrialsVabysmo Improves Vision and Retinal Anatomy in Real-World VOYAGER Study Vabysmo Improves Vision and Retinal Anatomy in Real-World VOYAGER Study Read Post »
Clinical TrialsPfizer’s Tilrekimig Achieves EASI-75 Across Doses in Phase 2 Atopic D... Pfizer’s Tilrekimig Achieves EASI-75 Across Doses in Phase 2 Atopic D... Read Post »
Clinical TrialsSurvodutide Achieves 13.1% Weight Loss in Phase III Trial Survodutide Achieves 13.1% Weight Loss in Phase III Trial Read Post »
Clinical TrialsGiredestrant Combination Cuts Breast Cancer Progression Risk Up to 62% in e... Giredestrant Combination Cuts Breast Cancer Progression Risk Up to 62% in e... Read Post »
Clinical TrialsBempikibart Maintains Responses After Treatment Discontinuation in Alopecia... Bempikibart Maintains Responses After Treatment Discontinuation in Alopecia... Read Post »
Clinical TrialsTulisokibart Meets Phase 2b Endpoint in Hidradenitis Suppurativa Tulisokibart Meets Phase 2b Endpoint in Hidradenitis Suppurativa Read Post »
Clinical TrialsRademikibart Reduces Treatment Failure by 81% in Phase 2 COPD Exacerbation ... Rademikibart Reduces Treatment Failure by 81% in Phase 2 COPD Exacerbation ... Read Post »
Clinical TrialsVanda’s Tasimelteon Advances Sleep Onset in Phase III Delayed Sleep-Wake ... Vanda’s Tasimelteon Advances Sleep Onset in Phase III Delayed Sleep-Wake ... Read Post »
Clinical TrialsAbbVie’s ABBV-295 Shows Up to 9.8% Weight Reduction in Phase 1 Study AbbVie’s ABBV-295 Shows Up to 9.8% Weight Reduction in Phase 1 Study Read Post »
Clinical TrialsZumilokibart Phase 2 Results Show EASI-75 Benefit in Atopic Dermatitis Zumilokibart Phase 2 Results Show EASI-75 Benefit in Atopic Dermatitis Read Post »
Clinical TrialsGalderma’s Nemluvio Shows Sustained Atopic Dermatitis Benefits in 3-Year ... Galderma’s Nemluvio Shows Sustained Atopic Dermatitis Benefits in 3-Year ... Read Post »
Clinical TrialsOral Safiglipron Demonstrates Glycemic Efficacy in Phase 3 Trial of Early T... Oral Safiglipron Demonstrates Glycemic Efficacy in Phase 3 Trial of Early T... Read Post »
Clinical TrialsPetrelintide Achieves Double-Digit Weight Loss with Placebo-Like GI Profile... Petrelintide Achieves Double-Digit Weight Loss with Placebo-Like GI Profile... Read Post »
Clinical TrialsRetatrutide Shows Up to 20.8% Weight Loss and A1C Reduction in TRIUMPH-2 Tr... Retatrutide Shows Up to 20.8% Weight Loss and A1C Reduction in TRIUMPH-2 Tr... Read Post »
Clinical TrialsDescartes-08 Retreatment Sustains Clinical Improvements in Generalized Myas... Descartes-08 Retreatment Sustains Clinical Improvements in Generalized Myas... Read Post »
Clinical TrialsTectonic Reports Favorable Phase 1a Results for TX2100 in Hemorrhagic Telan... Tectonic Reports Favorable Phase 1a Results for TX2100 in Hemorrhagic Telan... Read Post »
Clinical TrialsFoundayo 17.2 mg Shows Greater Weight Loss and A1C Reduction Than Oral Sema... Foundayo 17.2 mg Shows Greater Weight Loss and A1C Reduction Than Oral Sema... Read Post »
New Drug ApprovalFDA Approves Gazyva (Obinutuzumab) for Idiopathic Nephrotic Syndrome in Pat... FDA Approves Gazyva (Obinutuzumab) for Idiopathic Nephrotic Syndrome in Pat... Read Post »
Clinical TrialsMirum’ Brelovitug Meets Phase 3 Endpoint in Chronic Hepatitis Delta Mirum’ Brelovitug Meets Phase 3 Endpoint in Chronic Hepatitis Delta Read Post »
